Background {#Sec1}
==========

Legumes are fruits or seeds of a plant belonging to the family Fabaceae and are a popular food source in the traditional diets of many regions in the world. Well-known legumes include peas, beans, [lentils](https://en.wikipedia.org/wiki/Lentil), lupins, chickpeas, carob, soybeans, peanuts, and tamarind. They provide proteins, complex carbohydrates, and soluble and insoluble fibers. Legumes also contain a number of phytochemicals and antioxidants which include isoflavones, lignans, phytoestrogens, alkaloids, saponins, phytates, protease, and chymotrypsin inhibitors as well as micronutrients such as iron, copper, and manganese. Consumption of legumes in general plays a role in the prevention of cancer, cardiovascular disease, osteoporosis, and chronic degenerative diseases \[[@CR1]--[@CR3]\]. Furthermore, legumes have a low glycemic index, ranging from 10 to 40. In general, a serving of legumes (\~ 100 g fresh weight) provides 115 cal, 20 g of carbohydrates, 7--9 g of fiber, 8 g of protein, and 1 g of fat \[[@CR4]\].

Legumes, and in particular soy, constitute an important part of the diet for the majority of Asian population, and many studies have investigated their potential health promoting effects. Soybeans and soy-based food products contain uniquely high isoflavone content \~ 1--3 mg isoflavones/g protein, and one serving of traditional soy foods provides \~ 25--40 mg isoflavones \[[@CR5]\] as compared to other commonly consumed plant foods. In fact, USDA Database on the isoflavone content of the selected foods \[[@CR6]\] has reported very high total isoflavone content from soybean and soy-based products as compared to other vegetables and foods. Of the 114 commonly consumed vegetables of Europe analyzed, the foods derived from soy contained isoflavone concentration (500--1400 mg daidzein and genistein/kg) at least two orders of magnitude higher than the next richest isoflavone food (raw mung beansprouts; 6 mg/kg) and several orders of magnitude higher concentration than the non-leguminous sources \[[@CR7]\]. Consumption of an isoflavone rich soy diet has been linked to improved health outcomes in a number of studies \[[@CR5], [@CR8]--[@CR10]\]. These health benefits may arise in part due to the presence of various isoflavonoid components such as daidzein, genistein, and glycitein which were characteristic of soy possessing numerous biological functions \[[@CR5]\]. These isoflavonoids are found in conjugated form with either glucose or 6″-*O*-malonyl- or 6″-*O*-acetylglucose in plants \[[@CR11]\]. Daidzein is further metabolized by intestinal gut bacteria to equol, *O*-desmethylangolensin (*O*-DMA), dihydrodaidzein, and *cis*-4-OH-equol, while genistein is further metabolized to dihydrogenistein and 6'-OH-*O*-DMA \[[@CR12], [@CR13]\]. The beneficial effects of soy seem to be related to the combination of these compounds and not any one in particular. For example, daidzein and genistein were reported to have a synergistic effect on inhibiting cell proliferation and inducing apoptosis of prostate cancer cells \[[@CR14]\]. In addition, these compounds and equol were also proposed to be antiestrogenic, antioxidative, and anticarcinogenic and may protect against chronic diseases such as hormone-dependent cancer, cardiovascular diseases, and osteoporosis \[[@CR15]--[@CR19]\]. However, it is worth noting that a few studies considering estrogenic effects of dietary soy phytoestrogens have demonstrated that the isoflavones promote growth of ER-positive breast cancer cells under both in vitro as well as in vivo conditions \[[@CR20]--[@CR22]\]. With respect to dietary pulses, a sub-group of legumes, dietary intake has been associated with reduced chronic disease risks for cardiovascular disease and cancer \[[@CR23]\], as well as with improvements in intermediate cardiovascular disease risk factors, such as blood pressure, dyslipidemia, glycemic control, and weight management \[[@CR23]--[@CR28]\]. Pulses also provide a valuable means of lowering the glycaemic-index (GI) of the diet \[[@CR28]\].

Due to the health benefits of legumes, there is a growing interest in assessing their dietary intake across different populations. In order to achieve this to a high standard, it is pertinent that we have more accurate and reliable assessment tools to monitor their intake. The classical approaches of data collection tools such as food frequency questionnaires (FFQ), food dairies, and 24-h dietary recalls are associated with a number of errors \[[@CR29]--[@CR33]\]. Hence, there is a growing need for more objective measures of intake, and biomarkers have emerged as having great potential in this field. Such biomarkers should be able to reflect the differences in dietary intakes across a number of population types \[[@CR34]\].

The objective of this paper was to perform a systematic review of the literature and summarize the information from observational and human intervention studies on the biomarkers of legumes intake and also evaluate the validity, reproducibility, and sensitivity of the proposed markers that could potentially be useful indicators of legume consumption.

Search methodology {#Sec2}
==================

The reviewing process made use of elements of Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement \[[@CR35]\], which were relevant for a search for literature on biomarkers. The search methodology was also followed in accordance with the guidelines for biomarkers of food intake reviews (BFIRev) \[[@CR36]\]. The search process included results until 16 February 2018. In brief, original research papers and reviews were searched in three databases (PubMed, Scopus, and ISI Web of Knowledge) using combinations of the grouped search terms (legume OR bean OR pea) AND (biomarker\* OR marker\* OR metabolite\* OR biokinetics OR biotransformation) AND (trial OR experiment OR study OR intervention) AND (human\* OR men OR women OR patient\* OR volunteer\*) AND (urine OR plasma OR serum OR blood OR excretion) AND (intake OR meal OR diet OR ingestion OR consumption OR eating OR drink\*). The research was limited to papers in English language, while no restriction was applied for the publication dates. The research papers identifying or using potential biomarkers of intake for the foods were selected by one or more skilled researcher from the list of retrieved references taking into consideration inclusion criteria with literature focused on intervention studies in which participants consume known amount of specific foods and biological samples collected and also population studies. The exclusion criteria include literature reported with reference to effect of physiology, drug metabolism, in vitro studies, food analysis studies, animal studies, inappropriate study designs, and non-specific articles to legumes food group \[[@CR36]\] as outlined in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram of the study selection

Considering the list of discriminating metabolites obtained from the primary search, a secondary search was performed to identify other foods containing the same biomarkers or precursors and to determine the apparent specificity of the compound of interest. In this second step, PubMed, Scopus, and Web of Science were used as search platforms and the compounds checked for their specificity were genistein, daidzein, dihydrogenistein, dihydrodaidzein, enterodiol, enterolactone, matairesinol, *O*-DMA, glycitein, kaempferol, dimethylamine, glutamine, 3-methylhistidine, trigonelline, pipecolic acid, indolepropionate, *S*-methylcysteine, and *N*-acetyl-ornithine and their synonyms (Additional file [1](#MOESM1){ref-type="media"}: Table S1). For each of these potential biomarkers identified, an additional search was conducted using the following search criteria ("the name and synonyms of the compound" OR "the name and synonyms of any parent compound") AND (biomarker\* OR marker\* OR metabolite\* OR biokinetics OR biotransformation) AND (trial OR experiment OR study OR intervention) AND (human\* OR men OR women OR patient\* OR volunteer\*) AND (urine OR plasma OR serum OR blood OR excretion) AND (intake OR meal OR diet OR ingestion OR consumption OR eating OR drink\*).

The validity of candidate biomarkers obtained from the above search was further assessed through a consensus-based procedure which evaluated a set of the most important criteria for systematic evaluation of biomarkers of food intake. The scoring scheme presented in this review aimed to address criteria which include plausibility, dose-response, time-response, robustness, reliability, stability, analytical performance, and inter-laboratory reproducibility (Table [2](#Tab2){ref-type="table"}). A detailed explanation of critical assessment of the criteria chosen for biomarker validation was previously presented \[[@CR37]\].

Results and discussion {#Sec3}
======================

The literature search performed identified a total of 2139 articles from the three databases, and a flow diagram of the study selection is represented in Fig. [1](#Fig1){ref-type="fig"}. A total of 1922 articles were obtained after removal of duplicates using Endnote X7.4. Of these, a total of 70 articles were selected after screening on the basis of title and abstract. Exclusion criteria for the remaining 1852 articles included the following: effect on physiology, effect on drug metabolism, in vitro studies, food analysis, and other articles related to antioxidant markers, disease/health markers, oxidative stress markers, articles not relevant to intake biomarkers, and animal studies. Full texts of the 70 papers were downloaded and assessed further for exclusion/inclusion criteria. Exclusion criteria at this stage included animal studies, inappropriate study design and articles not specific to legume intake. In total, 44 articles were retained and used for the development of the tables. Table [1](#Tab1){ref-type="table"} provides a summary of the selected studies, including the candidate biomarkers for legumes/beans/peas intake identified through this search process.Table 1List of reported putative legume biomarkers of intakeDietary factorSubjectStudy designNumber of subjectsAnalytical methodSample typeDiscriminating metabolites/candidate biomarkersReferenceSoy beans/tofuHuman (M/F)Cross-sectional study98GC-MSUrine (24 h)Genistein\
Daidzein\
*O*-DMA\[[@CR41]\]Soy-based foodsHuman (F)Cross-sectional study102HPLCUrine (24 h)Genistein\
Daidzein\
*O*-DMA\
Glycitein\[[@CR44]\]Soy-based foodsHuman (F)Cross-sectional study60HPLCUrineGenistein\
Daidzein\
*O*-DMA\
Glycitein\[[@CR39]\]Soy-based foodsHuman (M/F)Cross-sectional study147HPLCUrine (spot)Genistein\
Daidzein\
*O*-DMA\
Glycitein\
Equol\[[@CR38]\]Soy proteinHuman (M/F)Cross-sectional study100HPLC-MSUrine (overnight)Genistein\
Daidzein\
Equol\[[@CR40]\]Soy-based foodsHuman (F)Cross sectional study27/451GC-MSUrine (24 h, overnight)Genistein\
Daidzein\[[@CR43]\]Soy milkHuman (F)Observational study159MSUrine (24 h)Equol\[[@CR87]\]Soy-based foodsHuman (F)Cross section363GC-MSUrine (2 Overnight, 48 h apart)Genistein\
Daidzein\
*O*-DMA\
Equol\[[@CR42]\]Soy-based foodsHuman (M/F)Cross-sectional study77LC-MSPlasma (fasting)Genistein\
Daidzein\[[@CR46]\]Soy-based foodsHuman (F)Cross-sectional study80Flouroimmuno assayPlasmaGenistein\
Daidzein\[[@CR45]\]Soy-based foodsHuman (F)Cross-sectional study1823LC-coularray, LC-MSSerum (non-fasting)Genistein\
Daidzein\[[@CR49]\]Soy-based foods and supplementsHuman (F)Cross-sectional study96LC-MSPlasma (fasting)Genistein\
Daidzein\[[@CR47]\]Soy-based foodsHuman (F)Case Control Study97 (Cases) 97 (Control)Isotope Dilution Electrospray Tandem Mass SpectrometryPlasma (randomly timed)Genistein\
Daidzein\
Equol\
Dihydrogenistein Dihydrodaidzein\[[@CR48]\]Soy bean productsHuman (M)Intervention study17GC-MSUrine (24 h)Genistein\
Daidzein\
*O*-DMA\
Equol\
Enterodiol\
Enterolactone\
Matairesinol\[[@CR56]\]Soy-based foodsHuman (F)Intervention study18HPLC-MSUrineGenistein\
Daidzein\
*O*-DMA\
Glycitein\
Equol\[[@CR90]\]Soymilk powderHuman (F)Acute study12HPLCUrine (0--24 h after intake)Genistein\
Daidzein\[[@CR19]\]Soy bean powder (Kinako)Human (M)Acute study7GC-MSUrine (0--24 h)Genistein\
Daidzein\
*O*-DMA\
Equol\[[@CR89]\]Soy nutsHuman (F)Acute study10GC-MSUrine (0--12 h for 5 days)Genistein\
Daidzein\
Equol\[[@CR68]\]Soymilk-based beveragesHuman (M/F)Acute study12LC-MSUrine (0--48 h)Genistein\
Daidzein\
Glycitein\[[@CR59]\]Soy isoflavonesHuman (F)Intervention study (30 days)\
Intervention study (60 days)27\
12ELISAUrine (24 h)Genistein\
Daidzein\
Equol\[[@CR71]\]Soy capsules (Phytosoya)Human (M)Acute study12ELISAUrine (0-24 h)Genistein\
Daidzein\
Equol\[[@CR78]\]Soy-based foodsHuman (M/F)Intervention study20GC-MSUrine (24 h)Genistein\
Daidzein\
*O*-DMA\
Equol\
Enterodiol\
Enterolactone\[[@CR52]\]Soy-based foodsHuman (F)Intervention study43LC-MSUrine (overnight)Genistein\
Daidzein\
Equol\[[@CR81]\]Soy-based foodsHuman (F)Intervention study350LC-MSUrine (overnight, spot)Genistein\
Daidzein\
*O*-DMA\
Equol\
Glycitein\
Dihydrogenistein Dihydrodaidzein\[[@CR58]\]Soy flourHuman (M/F)Acute study12GC-MSUrine (0--24 h on 0 days, 3 days, 4 days, 5 days)Genistein\
Daidzein\
*O*-DMA\
Equol\
Glycitein\
Dihydrodaidzein\
Enterolactone\[[@CR50]\]Soy protein beverageHuman (M/F)Acute study60GC-MSUrine (0--24 h on 4 days)Equol\
Daidzen\
Genistein\
*O*-DMA\[[@CR80]\]Soy milk, Miso soupHuman (F)Intervention study21LC-MSUrine (overnight, spot) for 6 daysDaidzein\
Genistein\
Equol\[[@CR61]\]Soy milkHuman (F)Acute study6GC-FIDUrine (1--4 days, 16--18 days, and 30--32 days)Daidzein\
Genistein\
Equol\[[@CR79]\]Soy-based foodsHuman (F)Intervention study350LC-MSUrine (overnight, spot)Equol\
Daidzein\[[@CR84]\]Soy-based dietHuman (F)Intervention study256HPLC; LC-MS/MSUrine (overnight)Total isoflavone excretion\[[@CR73]\]Commercial soy preparationHuman (M)Intervention study7GC-MSUrine (0--24 h)Daidzein\
Daidzein glucoside\
Dihydrodaidzein\
*O*-DMA\
Equol\[[@CR63]\]Soy flour-based mealHuman (M)Acute study6HPLCPlasma (0--35 h after intake)Genistein\
Daidzein\[[@CR67]\]Soy extract capsule/Soy beverageHuman (F)Acute study12HPLCPlasma (0--32 h after intake)Genistein\
Daidzein\[[@CR69]\]Soymilk powderHuman (F)Acute study12HPLCPlasma (0--24 h after intake)Genistein\
Daidzein\[[@CR19]\]Soy protein powderHuman (M)Intervention study20GC-MSPlasmaGenistein\
Daidzein\[[@CR54]\]Soy bean powder (Kinako)Human (M)Acute study7GC-MSPlasma (0--72 h after intake)Genistein\
Daidzein\
*O*-DMA\
Equol\[[@CR89]\]Soy nutsHuman (F)Acute study10HPLC-MS\
GC-MSSerum (0--48 h)Genistein\
Daidzein\
Equol\[[@CR68]\]Soymilk-based beveragesHuman (M/F)Acute study12LC-MSSerum (0--24 h)Genistein\
Daidzein\
Glycitein\[[@CR59]\]Soy isoflavonesHuman (F)Intervention study\
Intervention study27\
12ELISAPlasma (fasting)Genistein\
Daidzein\
Equol\[[@CR71]\]Soy capsules (Phytosoya)Human (M)Acute study12ELISAPlasma (0--48 h)Genistein\
Daidzein\
Equol\[[@CR78]\]Soy-based foods and supplementsHuman (F)Cross-sectional study96LC-MSPlasma (fasting)Genistein\
Daidzein\[[@CR47]\]Soy bean extractsHuman (M/F)\
Human (M)Acute study\
Intervention study16\
8HPLC\
HPLCPlasma (0-24 h after intake)\
Plasma (non-fasting)Genistein\
Daidzein\[[@CR62]\]Soy-based foodsHuman (F)Intervention study350LC-MSPlasma (baseline, every 6 months for 2.5 years)Genistein\
Daidzein\
*O*-DMA\
Equol\
Glycitein\
Dihydrogenistein Dihydrodaidzein\[[@CR58]\]Soy-based foodsHuman (F)Intervention study350LC-MSPlasma (baseline, every 6 months for 2.5 years)Equol\
Daidzein\[[@CR84]\]Commercial Soy isoflavone supplementsHuman (F)Acute study19GC-MSPlasma (0--48 h)Genistein\
Daidzein\
Genistin\
Daidzin\[[@CR64]\]Commercial soy preparationHuman (M)Intervention study7GC-MSPlasma (0--48 h)Daidzein\
Daidzein glucoside\
Dihydrodaidzein\
*O*-DMA\
Equol\[[@CR63]\]Soy bean powder (Kinako)Human (M)Acute study7GC-MSFeces (24-72 h)Genistein\
Daidzein\
*O*-DMA\
Equol\[[@CR89]\]Dry beansHuman (M/F)Observational study106LC-MS; GC-MSSerum (fasting)Pipecolic acid\
*S*-Methyl cysteine\
*N*-Acetylornithine\
Trigonelline\
Indole propionate\[[@CR94]\]Dry beansHuman (M)\
Mouse (M)Intervention study\
Intervention study46\
12LC-MS; GC-MS\
LC-MS; GC-MSSerum (fasting)\
SerumPipecolic acid\
*S*-Methyl cysteine\
*N*-Acetylornithine\
Trigonelline\
Indole propionate\
Pipecolic acid\
*S*-Methyl cysteine\
*N*-Acetylornithine\[[@CR94]\]BeansHuman (M/F)Acute study7HPLCUrine (0--24 h after intake)Kaempferol\[[@CR95]\]Green peasHuman (M/F)Intervention study9NMRUrine (0--3 days)Trigonelline\[[@CR98]\]PulsesHuman (M/F)Observational study50NMRSpot urineDimethylamine\
Glutamine 3-Methylhistidine\[[@CR97]\]

Cross-sectional studies reporting on isoflavones and their metabolites as markers of soy intake {#Sec4}
-----------------------------------------------------------------------------------------------

Examination of cross-sectional studies revealed that a number of studies investigated the isoflavones and their metabolites such as genistein, daidzein, glycitein, and *O*-DMA in biological samples such as urine and blood (serum and plasma) following the consumption of soy or soy-based foods (Table [1](#Tab1){ref-type="table"}).

A study conducted in 147 Singaporean Chinese with spot urine samples demonstrated a statistically significant, dose-dependent association between frequency of overall soy intake and levels of urinary daidzein (*p* = 0.03) and sum of urinary daidzein, genistein, and glycitein (*P* = 0.04) \[[@CR38]\]. A dose-response relationship was also observed between dietary soy consumption and urinary excretion rates of daidzein, genistein, and glycitein as well as with total isoflavones (*p* ≤ 0.05) in Chinese women (*n* = 60) \[[@CR39]\]. There were also positive correlations established between urinary isoflavones excretion and the amount of soy food, soy protein, and soy isoflavones intake (*r* = 0.50, *p* \< 0.001, *r* = 0.53, *p* \< 0.001 and *r* = 0.54, *p* \< 0.001, respectively). Similarly, another study examining a Western population (*n* = 100) showed significant correlations between soy protein intake from 24-h recalls with daidzein (*r* = 0.72, (CI) 0.43, 0.96), genistein (*r* = 0.67, (CI) 0.43, 0.91), and total isoflavones (*r* = 0.72, (CI) 0.47, 0.98) \[[@CR40]\]. Additionally, between FFQs and urinary excretion, the correlations were (*r* = 0.50, (CI) 0.32, 0.65), (*r* = 0.48 (CI) 0.29, 0.61) and (*r* = 0.50 (CI): 0.32, 0.64) for daidzein, genistein, and total isoflavones, respectively \[[@CR40]\]. Significant correlations were reported between intake of soy foods through FFQ and 5-day diet records, with urinary genistein (*r* = 0.40, *p* = 0.0001), *O*-DMA (*r* = 0.37, *p* = 0.0002), daidzein (*r* = 0.34, *p* = 0.0007), and the sum of isoflavones (*r* = 0.39, *p* = 0.0001) in US men and women (*n* = 98) \[[@CR41]\]. In another US population study, positive correlations were demonstrated between self-reported soy intake and excretion of urinary isoflavones (*r* = 0.52, *p* \< 0.001 for dietary recall and *r* = 0.29, *p* \< 0.01 for FFQ) \[[@CR42]\]. In a US study (*n* = 451 women) \[[@CR43]\], 24-h urine sample measures were shown to be strongly correlated with overnight urine excretion for daidzein (*r* = 0.84) and genistein (*r* = 0.93). The 24-h urine sample measures were also correlated with soy food questionnaire (SFQ) estimates of daidzein (*r* = 0.48) and genistein (*r* = 0.54) intake \[[@CR43]\]. A significant correlation between isoflavones measured in an overnight urine and soy protein intake estimated by self-reported intake (dietary questionnaire) was also established in multiethnic population (*n* = 102), both in the previous 24 h (*r* = 0.61, *p* \< 0.0001) and in the past year (*r* = 0.32, *p* \< 0.0012) \[[@CR44]\]. Overall, significant correlations between soy intake and urinary isoflavones excretion either in spot, overnight, or 24-h urine samples were demonstrated suggesting that these compounds have the potential to serve as dietary biomarkers.

While the above studies have focused on isoflavone levels in urine, there was also evidence to support relationships in plasma and serum. A study of four groups of 20 premenopausal British women (*n* = 80) demonstrated significant correlations between dietary total soy intake estimated by FFQ and food diaries with plasma daidzein (*r* = 0.74--0.78, *p* \< 0.001) and genistein (*r* = 0.73--0.78, *p* \< 0.001) \[[@CR45]\]. Similarly, significant correlations were reported between genistein and daidzein intakes as determined by soy FFQ with plasma concentrations (*r* = 0.53 and 0.45) respectively in a Western population group (*n* = 77) \[[@CR46]\]. Furthermore, similar results were found in US postmenopausal women (*n* = 96) with correlations varying from 0.35 to 0.43 depending on the dietary intake instrument \[[@CR47]\]. A statistically significant (*p* = 0.002) threefold difference in mean plasma levels of total isoflavones was observed between women with high and low soy isoflavone intake levels as determined from FFQ \[[@CR48]\]. For the correlation between serum isoflavones levels and soy intake, a significant linear trend (*p* \< 0.01) was observed in serum isoflavones (daidzein and genistein) concentrations across increasing categories of soy food consumption estimated by FFQ in Asian women (*n* = 1823) \[[@CR49]\].

In summary, the cross-sectional studies demonstrated that there were positive correlations between soy intake with urinary, plasma, and serum isoflavones levels, mainly daidzein and genistein, in different population groups.

Acute and intervention studies reporting relationships between soy intake and isoflavones and their metabolites {#Sec5}
---------------------------------------------------------------------------------------------------------------

### Soy isoflavones {#Sec6}

The literature search identified a number of intervention studies which focused on soy-based diets and isoflavonoid excretion in different population groups (Table [1](#Tab1){ref-type="table"}). Various acute studies have reported increased isoflavonoid concentrations in blood and urine following consumption of soy-based foods (Table [1](#Tab1){ref-type="table"}). To understand the metabolic fate of dietary isoflavones in humans, a study examined 24-h urines from 12 healthy Caucasian male and female participants following 3 days of soy challenge: the urinary isoflavone levels (genistein, daidzein, glycitein) peaked more than 3.8-fold and returned to basal levels by day 4, while the major urinary metabolites (*O*-DMA, equol, 6-hydroxy-*O*-DMA, dihydrodaidzein) demonstrated a more significant increase of over 5- to 40-fold and progressively fell over days 4 and 5 \[[@CR50]\]. This marked variation among the major urinary isoflavonoid metabolites may reflect variability in an individual's ability to ferment isoflavones and the fat content of the diet \[[@CR51]\]. A randomized controlled crossover feeding study demonstrated that the urinary excretion of total isoflavones significantly increased with soy diet (normal basal diet plus 100 g tofu and 45 g of soy protein isolate served per day) consumption (26.01 ± 2.30 μmol/day) as compared to the vegetable free (0.75 μmol/day), carotenoid (0.51 μmol/day), and cruciferous vegetable diet (1.03 μmol/day) \[[@CR52]\]. Overall, the results from this study provide information on the utility of urinary isoflavones as biomarkers of soy intake.

In another study, the urinary recovery of daidzein levels were significantly higher than genistein (*p* \< 0.001), while the plasma concentrations of both isoflavones did not differ significantly (*p* \> 0.1) after single doses of 0.7, 1.3, and 2.0 mg isoflavones/kg body weight in soybean milk \[[@CR19]\]. Subsequently, a randomized, double-blind, crossover study involving four 9-day soy protein beverage supplementation periods established a positive dose-response between urinary isoflavones excretion and soy intake (*p* = 0.0001) with no significant difference between equol excretors and non-excretors \[[@CR53]\].

A study examining the repeated intake of consuming soy protein powder of about 60 g/day in a controlled intervention trial for over a period of 28 days demonstrated that the plasma isoflavone levels markedly increased on day 28 compared to day 0 with no change in the control group on a casein supplement diet \[[@CR54]\]. This result was in agreement with other related studies, which demonstrated an increase in isoflavonoid excretion following a soy challenge \[[@CR19], [@CR50], [@CR55], [@CR56]\].

Glycitein is a soy isoflavonoid which constitutes 5 to 10% of the total isoflavones in the soy beans \[[@CR57]\]. A few cross-sectional studies have reported urinary excretion of glycitein \[[@CR38], [@CR39], [@CR44]\], but the excretion levels are low compared to genistein and daidzein \[[@CR58]\]. Maximum serum concentration for glycitein attained after ingestion of aglycone and glucosidic forms of soy beverage did not differ significantly (0.07--0.09 μmol/L), and maximum urinary excretion was reported to be \~ 3 μmol \[[@CR59]\]. Similarly, maximum glycitein plasma concentration of \~ 200 ng/ml and maximum glycitein urinary concentration of 11,000 ng/ml were reported in a bioavailability study \[[@CR60]\]. A large soy intervention trial demonstrated a three- to fourfold increase in glycitein levels in plasma, overnight urine, and spot urine was observed in the soy group compared to the placebo. However, the magnitude of increase was smaller compared to major soy isoflavones genistein and daidzein \[[@CR58]\].

Several studies have also reported differences in isoflavone excretion with respect to the type of soy foods with most interest in the difference between fermented and non-fermented sources. A study comparing the effects of fermented and non-fermented soy product consumption demonstrated that the urinary isoflavone recovery of genistein and daidzein was higher (*p* \< 0.002) when the subjects consumed tempeh (fermented) compared to the soybean pieces diet \[[@CR56]\]. This suggests that the fermented products, due to the hydrolysis of isoflavone glucosides to their corresponding aglycones could have increased availability of the isoflavones. In contrast, urinary isoflavonoid excretion showed no significant difference upon consumption of soymilk (non-fermented) compared to miso soup (fermented) (*p* = 0.87) \[[@CR61]\].

Similarly, a study comparing the effects of fermented and non-fermented soy product consumption demonstrated that the plasma concentrations of genistein and daidzein were more than twice and five times higher (*p* \< 0.05) when subjects consumed fermented soybean extract compared to non-fermented soybean extract \[[@CR62]\]. Similar results were reported for total isoflavones with higher serum isoflavone concentrations (\~ 2 μmol/L) attained with fermented soymilk ingestion compared to non-fermented soymilk (\~ 0.94 μmol/L) \[[@CR59]\]. In contrast, reports following ingestion of commercial soy supplements have reported that plasma isoflavone concentrations were higher following ingestion of glucosidic forms compared to aglycone forms \[[@CR63], [@CR64]\]. However, it should also be noted that hydrolysis of isoflavone glycosides to their corresponding aglycones did not seem to alter plasma concentrations in some studies \[[@CR65], [@CR66]\].

Overall, the urinary excretion levels and plasma concentrations of soy isoflavones were reported to have variable responses to the consumption of isoflavone aglycone- and isoflavone glucoside-rich foods.

### Pharmacokinetics of isoflavones {#Sec7}

A number of studies investigated the pharmacokinetic behavior of isoflavones following soy intake. In all studies, the shapes of the plasma appearance and disappearance curves with respect to time exhibited biphasic pattern as a result of enterohepatic circulation of the compounds. Peak plasma concentration of isoflavones following consumption of a soy-based meal was reported for genistein at 8.42 ± 0.69 h (*t*~1/2~ = 5.7 ± 1.3 h) and daidzein at 7.42 ± 0.74 h (*t*~1/2~ = 4.7 ± 1.1 h) \[[@CR67]\]. Similarly, genistein was reported as having a longer half-life (8.36 h) compared to daidzein (5.79 h) following consumption of 60 g of kinako (baked soybean powder) \[[@CR59]\]. Peak serum concentrations of daidzein and genistein on average were attained at 6.9 ± 0.7 h and 6.5 ± 1.0 h, respectively, and their corresponding elimination half-lives were reported as 8 and 10.1 h, respectively, following consumption of 10, 20, or 40 g of soy nuts \[[@CR68]\]. A curvilinear relationship was established between bioavailability for daidzein and genistein and the increased amount of soy nuts intake. This suggests a decrease in serum concentrations measured at increasing dosage levels. The same study revealed that most of the excreted urinary isoflavones were eliminated within the first 2 days following consumption of soy nuts at different doses. However, the urinary daidzein excretion decreased from approximately 63 to 44%, while the urinary genistein excretion decreased from 25 to 15% upon increased amount of soy nuts intake from 10 to 40 g. This non-linear pharmacokinetic behavior over a dose range reveals that optimum steady state isoflavone concentrations can be achieved by multiple intakes of soy foods at regular intervals of time than a single high dosage soy product \[[@CR68]\]. Similarly, a randomized two-phase crossover study reported peak plasma concentrations of daidzein and genistein on average attained at 6.08 h and 6.37 h, respectively, and their corresponding half-lives were 7.17 h and 7.7 h, respectively \[[@CR69]\]. Typically in all of the studies, urinary recovery of genistein and daidzein is complete within 24--36 h \[[@CR70]\]. According to the evidence obtained from the literature, both urine and plasma can be considered suitable biofluids to measure soy intake.

### Chronic ingestion of soy isoflavones {#Sec8}

A study in post-menopausal women who chronically ingested the commercial soy-based preparation Prevastein (46.19 g of total isoflavones expressed in the aglycone form per 100 g of preparation) for 30 and 60 days demonstrated that the urinary and plasma concentrations of genistein, daidzein, and equol remained constant from day 15 until the end of experimental period \[[@CR71]\]. The data suggest that chronic ingestion could lead to a saturation point and optimum steady state biofluid concentrations can be achieved consistently with adequate intake of soy foods or supplements. However, from a biomarker view point, this may indicate a limitation for estimation of high intakes \[[@CR68], [@CR71]\]. An intervention study in young girls who consumed either one daily serving of soymilk (8.5 oz) or soy nuts (1 oz) for 8-week period demonstrated that urinary excretion of soy isoflavones increased by almost sixfold from baseline (23.3 to 142 nmol/mg creatinine). This finding was also reported to be consistent with the 3-day food record which showed a significant increase in isoflavone intake (5.4 to 32.6 mg/day) during the intervention period \[[@CR72]\].

While there are many studies focused on concentration levels of isoflavones present in the biofluids following consumption of a range of soy foods, these studies have limited number of subjects and some of the studies lack repeated collection of biofluids. A large randomized, double-blind soy intervention trial with 350 postmenopausal women for 3 years established high correlations between isoflavone measurements of overnight urine, spot urine, and plasma with Pearson correlations ranging between 0.60 and 0.94 \[[@CR58]\]. All three matrices showed significantly high isoflavone quantitative differences of up to 3--19-fold between placebo and soy group and also highly significant correlations between mean isoflavone values and soy doses, but not in the placebo group. In another two randomized soy trials conducted among 256 premenopausal women consuming high (\~ 50 mg isoflavones/day) and low (\~ 10 mg isoflavones/day) soy diets, urinary isoflavonoid excretion significantly correlated to dietary isoflavone intake (*r* = 0.51, AUC = 0.85; *p* \< 0.0001) \[[@CR73]\]. Overall, these studies provide further support for the use of isoflavones as biomarkers of dietary soy intake.

Soybeans are consumed mainly as processed soy products such as tofu, milk, nuts, and protein isolate powder. The influence of soy food matrix and the effect of industrial processing has resulted in varied isoflavone contents in soy-based products \[[@CR74], [@CR75]\]. The varied degree of processing conditions has also influenced the metabolism, pharmacokinetics, and bioavailability of soy isoflavones \[[@CR55], [@CR64], [@CR76], [@CR77]\]. However, our review concentrated on covering information on potential biomarkers obtained from soy and soy-based food products rather than trying to understand the influence of abovementioned conditions on the bioavailability of biomarkers. Furthermore, it should be noted that the biomarkers cannot distinguish between food and supplement sources.

### Soy isoflavone metabolites {#Sec9}

A number of soy isoflavone metabolites are found in the circulation. The following section will highlight the key isoflavone metabolites found in the literature review.

Equol is a major isoflavonoid estrogen metabolite produced from daidzein by gut microbiota and is produced by \~ 30--40% of individuals after a soy challenge (named "equol producers") \[[@CR70], [@CR78]\]. A chronic soy exposure study demonstrated that the urinary recovery of equol increased by 3--100-fold (*p* \< 0.05) over 4 weeks of daily soy ingestion \[[@CR79]\]. Similarly, a study examining the prevalence of equol excretion in both male and female individuals revealed that 35% of the participants among the 60 were found to excrete equol following soy protein beverage consumption after 3 days \[[@CR80]\]. However, the common isoflavones excreted after ingestion of soy-based foods such as daidzein, genistein, and *O*-DMA was similar between equol excretors and non-excretors in both men and women \[[@CR80]\]. A similar study demonstrated an increase in equol production in older women, while the total excretion of isoflavones remained the same after a standardized dose of soy milk among three generations of American-Japanese women \[[@CR81]\]. The differences in excretion could in part be attributed to differential gut microbiota composition with age and differential habitual dietary compositions \[[@CR51], [@CR82], [@CR83]\]. Equol production was studied over a period of 3 years, and results indicated a high intraindividual variability \[[@CR84]\]. However, in other studies, equol production was reported to be relatively stable over time \[[@CR85], [@CR86]\]. Such differences in equol production could be due to dietary factors such as minor differences in intake of micronutrients \[[@CR87]\], but further research needs to be done to consider other factors responsible for variation in equol production.

*O*-DMA is an isoflavonoid estrogen metabolite formed when daidzein is metabolized to dihydrodaidzein by intestinal bacteria in the large intestine and further undergoes ring cleavage \[[@CR88]\]. Urinary excretion of *O*-DMA was reported to be generally higher when subjects consumed soy-based foods \[[@CR50], [@CR52], [@CR56], [@CR53], [@CR89]\]. A randomized crossover study also demonstrated that *O*-DMA appears in plasma after \~ 6--8 h post-consumption of daidzein rich soy isoflavone preparation and also observed almost a twofold increase after ingestion of pure daidzein glucoside compared to the aglycone form. Urinary excretion levels of *O*-DMA were also two times higher following ingestion of the glucoside form compared to aglycone form \[[@CR63]\]. In a large soy intervention trial, \~ 10-fold increase in *O*-DMA levels in plasma, overnight urine, and spot urine was observed in the soy group fed with soy beverage powder and soy bars compared to the placebo fed with protein isolates and bars with no isoflavone content \[[@CR58]\]. A lower urinary isoflavone excretion value for *O*-DMA was reported in the equol excretors probably due to conversion of daidzein to equol \[[@CR90]\].

Additionally, some studies have reported the urinary dihydrogenistein and dihydrodaidzein (intermediate products of soy isoflavone metabolism) levels post-consumption of soy-based foods \[[@CR50], [@CR91], [@CR92]\]. Consumption of soy compared to placebo resulted in \~ 4--7 fold higher dihydrogenistein and dihydrodaidzein \[[@CR58]\]. While these soy isoflavone metabolites reveal interesting metabolic information, it remains to be determined if they are useful as biomarkers of soy intake.

### Lignan phytoestrogens {#Sec10}

A few studies have reported either low or no association of lignans in biofluids to consumption of soy or soy-based foods. The urinary excretion of lignans enterodiol and enterolactone was reported to be low after consumption of soy rich diet \[[@CR93]\] and fermented and unfermented soy products \[[@CR56]\]. The enterolactone levels were found to remain unaffected following a soy challenge \[[@CR50]\]. Furthermore, no differences in excretion levels of lignans were found following soy-based diet and basal diet consumption \[[@CR52]\]. Subsequently, the urinary excretion levels of lignans are high following consumption of other sources of lignans such as cruciferous vegetable diets (3.86 ± 0.21 μmol/day) as compared to soy diet (0.84 ± 0.21 μmol/day) \[[@CR52]\], and hence, lignans cannot be considered as markers of soy consumption.

Studies relating pulses intake to metabolites in biofluids {#Sec11}
----------------------------------------------------------

While most of the studies retrieved are focused on soybeans, there are a few studies which proposed metabolites related to pulses intake. A randomized controlled crossover human feeding study involving 46 middle-aged men following consumption of a high dry bean-enriched diet (250 g/day) for 4 weeks led to elevated serum levels of pipecolic acid, *S*-methyl cysteine, *N*-acetylornithine, trigonelline, and indole propionate \[[@CR94]\]. Based on a further study in which participants self-reported their dry bean intake, only pipecolic acid and *S*-methyl cysteine reflected dry bean consumption. Therefore, these two metabolites were proposed as useful markers of dry bean consumption \[[@CR94]\]. In a different study, maximum peak urinary excretion of kaempferol was observed after 2--8 h following consumption of cooked beans (*Phaseolus vulgaris* L.) \[[@CR95]\]. The average excretion was 6.1% and 5.4% of kaempferol dose for males and females respectively. However, although the excretion profiles were similar between subjects, a 6.72-fold inter-individual variation in excretion concentrations was reported, which was ascertained to variations in intestinal physiology \[[@CR95]\]. A study examining urinary exposure markers of a wide range of individual foods and food groups revealed that the most probable food exposure marker for green beans was an unsaturated aliphatic hydroxyl-dicarboxylic acid \[[@CR96]\]. An observational study aimed to characterize the urinary metabolomic fingerprinting revealed glutamine, dimethylamine, and 3-methylhistidine as candidate biomarkers of pulse consumption \[[@CR97]\]. A recent study identified trigonelline as urinary biomarker of pea intake although reported to be non-specific marker of pea consumption \[[@CR98]\]. Notwithstanding the substantial research performed on soy isoflavones, further research still needs to be performed in order to identify potential biomarkers of pulses and pulse-based foods in general.

Overall usefulness of the biomarkers {#Sec12}
------------------------------------

The assessment of data presented in Table [2](#Tab2){ref-type="table"} and the secondary search performed revealed that the compounds genistein and daidzein are present in very high concentrations in soybeans and in moderate concentrations in legume-based vegetables such as beansprouts, chickpeas, lentils, fava bean, and roots of kudzu wine \[[@CR7], [@CR99]\]. They are also present in lower concentrations in other fruits and vegetables such as potato, tomato, cabbage, turnip, pumpkin, and asparagus \[[@CR7]\]. Although there are some reports of excretion of daidzein and genistein and their precursors following consumption of red clover \[[@CR100]\], the higher concentrations following soy consumption make them highly specific markers of soy consumption as evidenced in the published studies. Moreover, genistein and daidzein were observed as having a dose-dependent relationship with soy intake in various observational studies \[[@CR38], [@CR39], [@CR44], [@CR46], [@CR47]\]. Dose-response effects after a single bolus ingestion of three different doses of soy isoflavones were also reported \[[@CR68]\]. The time-response relationship explaining the elimination half-life of genistein and daidzein \[[@CR64], [@CR89]\] as well as kinetics of repeated intake \[[@CR71]\] were also highlighted in this review. Both genistein and daidzein are also proven to be stable in urine and plasma at − 20 °C for almost 3 months \[[@CR101]\] and various quantification methods using LCMS and GCMS platforms for genistein and daidzein have been developed. The recovery %, limit of detection, and sensitivity and specificity of genistein and daidzein were reported in different analytical methods \[[@CR102]\]. A multi-laboratory validation study across seven different laboratories proposed to determine and quantify the isoflavone content in three soybean varieties showed a satisfactory interlaboratory precision \[[@CR103]\]. However, there are no reports of individual isoflavones reported for interlaboratory reproducibility. From a robustness point of view, while the cross-sectional studies have demonstrated significant associations with soy intake, a number of potential confounding factors such as gut microbial populations, intestinal transit time, and gender were identified. Furthermore, data also exists which demonstrates that plasma isoflavone concentrations were positively associated with age, fiber consumption, servings of fruits and vegetables, and dietary supplements \[[@CR98]\]. Consequently, additional research efforts are needed to establish more clearly the relationship between the biomarkers and habitual diet in larger population-based studies and after intake of complex meals in intervention studies with more number of subjects.Table 2Possible scoring scheme for legume intake biomarker validityFood itemMetabolitesBiofluid locationsQuestions12345678SoyGenisteinUrineYYYNNYYUPlasma/serumYYYNNYYUDihydrogenisteinUrineNUUNNUYUPlasma/serumNUUNNUYUDihydrodaidzeinUrineNUUNNUYUPlasma/serumNUYNNUYUEnterodiolUrineNUUNNUYUPlasma/serumNUUNNUYUEnterolactoneUrineNUUNNUYUPlasma/serumNUUNNUYUMatairesinolUrineNUUNNUYUPlasma/serumNUUNNUYUDaidzeinUrineYYYNNYYUPlasma/serumYYYNNYYUEquolUrineNUYNNUYUPlasma/serumNUYNNUYUO-desmethylangolensinUrineNUUNNUYUPlasma/serumNUYNNUYUGlyciteinUrineYUYNNUYUPlasma/serumYUYNNUYUPulsesKaempferolUrineNUYUUUYUDimethylamineUrineNUUUUUYUGlutamineUrineNUUUUUYU3-MethylhistidineUrineNUUUUYYUTrigonellineUrineNYUUUUNUPlasma/serumNUUNUUYUPipecolic acidPlasma/serumNUUYUUYUIndolepropionatePlasma/serumUUUNUUUUS-MethylcysteinePlasma/serumUUUYUUUU*N*-Acetyl-ornithinePlasma/serumUUUNUUUUPossible answers are Y (yes), N (No), or U (unknown or uncertain)Questions1. Is the marker compound plausible as a specific biomarker of food intake for the food or food group (chemical/biological plausibility)?2. Is there a dose-response relationship at relevant intake levels of the targeted food (quantitative aspect)?3. Is the biomarker kinetics described adequately to make a wise choice of sample type, frequency and time window (time-response)?4. Has the marker been shown to be robust after intake of complex meals reflecting dietary habits of the targeted population (robustness)?5. Has the marker been shown to compare well with other markers or questionnaire data for the same food/food group (reliability)?6. Is the marker chemically and biologically stable during biospecimen collection and storage, making measurements reliable and feasible (stability)?7. Are analytical variability (CV%), accuracy, sensitivity and specificity known as adequate for at least one reported analytical method (analytical performance)?8. Has the analysis been successfully reproduced in another laboratory (reproducibility)?

Regarding isoflavone metabolites *O*-DMA, dihydrogenistein, and dihydrodaidzein, the urinary excretion of these compounds was weakly associated with soy food intake \[[@CR104]\], and furthermore, these metabolized isoflavones are also reported to be present in human urine following red clover supplementation \[[@CR105]\]. Taken together, this suggests the non-specificity of these metabolites after soy intake.

From the studies examined, it is clear that genistein and daidzein represent biomarkers of soy intake in different population groups. The influence of gender on soy isoflavone excretion was reported with urinary genistein recovery found to be higher after consumption of soy-based foods in women, while no differences were observed in males. Urinary daidzein recovery was not affected by gender, but conversion to metabolite equol seems to be influenced by chemical composition of the isoflavones ingested and the dietary factors such as fiber and carbohydrate \[[@CR106]\]. Gender differences were also reported with longer half-lives for plasma genistein and daidzein in females as compared to males \[[@CR79]\]. Furthermore, another factor that needs to be considered is the effect of interindividual variation. Numerous studies have shown considerable interindividual variation between participants in the plasma and urinary concentrations of isoflavones \[[@CR19], [@CR79], [@CR107]\] and their metabolites especially equol demonstrating multifold interindividual variation \[[@CR51], [@CR80], [@CR107]\]. It might be caused due to differences in absorption and metabolism, differential gut microflora composition, genetic variation in transporter genes, dietary fat, carbohydrate, and fiber intake \[[@CR41], [@CR51], [@CR108]--[@CR110]\].

The lignan phytoestrogens enterodiol, enterolactone, and matairesinol are widely distributed in many plant classes, and their presence is more prevalent in whole grains and fiber-containing plant foods (wheat, oats, rye), oilseeds (flax seeds and sesame seeds), and various other fruits and vegetables \[[@CR70], [@CR93], [@CR111]\]. According to a study conducted at USDA \[[@CR112]\], high concentrations of lignans were reported for flaxseeds (28,800--94,500 μg/100 g), cereal grains (168.1--1084.1 μg/100 g), vegetables (389.1--6344 μg/100 g), and fruits (229--2354 μg/100 g), while lower levels were reported for soy (130--1268 μg/100 g). The urinary excretion levels of lignans as reported in the lignin phytoestrogen section is high after consumption of sources other than soy-based foods suggesting the limited role of soy as a specific source of lignan phytoestrogens.

In parallel, an additional search was conducted for compounds identified following pulse consumption to examine the candidate biomarkers for specificity for pulses. The assessment of data presented in Table [2](#Tab2){ref-type="table"} revealed that kaempferol is present in a wide range of edible plants such as tea, broccoli, cabbage, kale, leek, tomato, strawberries, and grapes \[[@CR113]\]. Consequently, kaempferol has been detected in biological samples after intake of other foods such as fruits and vegetables \[[@CR114], [@CR115]\], onions \[[@CR116], [@CR117]\], tea \[[@CR116], [@CR118]--[@CR121]\], other phenol-rich foods \[[@CR122]\], and other food sources \[[@CR123]--[@CR125]\]. Dimethylamine has been proposed as a marker of fish consumption \[[@CR126]\], while 3-methylhistidine is a marker of chicken intake \[[@CR127]\]. On the other hand, trigonelline has also been proposed as a biomarker of coffee with high concentrations reported after coffee intake \[[@CR128]--[@CR131]\]. Regarding pipecolic acid, it can be found in the urine or serum after consumption of black soybean peptide \[[@CR132]\] and whole grain-enriched diet \[[@CR133]\]; and indole propionate was reported as marker of red meat and eggs intake \[[@CR134]\]. On the other hand, no relevant papers were found to evaluate the specificity of *S*-methylcysteine and *N*-acetyl-ornithine. Based on the above information, the compounds detected in the biofluids after consumption of beans are also present in other food sources, and hence, none of these compounds could be considered as specific biomarkers of bean intake when evaluated alone.

Conclusions {#Sec13}
===========

Although many compounds have been suggested as biomarkers for soy, pulses, and legumes in general, the validation of these compounds against other markers for the same food/food group needs to be performed. Overall, genistein and daidzein could potentially be considered as relevant markers of soy considering various evidence from the literature such as dose-response relationships and the suitability for detecting both acute and habitual intake as evidenced from intervention and cross-sectional studies. In addition, both genistein and daidzein were proven as good estimates of soy intake as evidenced from long-term exposure studies further marking their status as validated biomarkers. Due to the dearth of information on biomarkers of pulses, further discovery and validation studies are needed in this area in order to identify reliable biomarkers of pulse intake.

Additional file
===============

 {#Sec14}

Additional file 1:**Table S1.** Keywords related to the name and synonyms of the each potential biomarker of soy/pulses intake used in the search strategy. (DOCX 17 kb)

FFQ

:   Food frequency questionnaire

*O*-DMA

:   *O*-Desmethylangolensin

SFQ

:   Soy food questionnaire
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